CDC says it’s too soon to assess risk posed by Covid subvariant

Anursepreparesadoseofthispastspring'sCovid-19boostershot.JacobKing/WPAPoolviaGettyImagesTheCentersfo DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr




explore

author：entertainment    Page View：787
Alexis Borisy
Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In
Previous article： Patients, doctors press FTC to beef up hospital merger scrutiny
Next article： Malaria cases in Florida and Texas: Here’s what you need to know